multiplemyelomahub.com - This article focuses on the addition of mAbs to standard triplet regimens as frontline treatment for newly diagnosed MM (NDMM), and their latest clinical...
# ASCO20
ASCO Educational Book - ...
Trastuzumab Deruxtecan Shakes Up HER2-Mutated NSCLC Treatment Paradigm
posted 12 hours
Shared 0 times
OncLive - Solange Peters, MD, discusses the promising clinical activity observed with trastuzumab deruxtecan in patients with HER2-mutated NSCLC, next steps for research, and other exciting...
American Society of Clinical Oncology - Membership in ASCO is essential for every early-career oncologist. Physicians enrolled in an oncology subspecialty training program gain access to the complete portfolio of...
Optimizing Outcomes in Prostate Cancer: Matching Treatment to Patient in the Modern Era | Live CME
posted 18 hours
Shared 0 times
www.gotoper.com - Optimizing Outcomes in Prostate Cancer: Matching Treatment...
know.lww.com - Findings from a phase III study showed that cediranib plus olaparib had similar activity to standard platinum-based chemotherapy in relapsed platinum-sensitive ovarian cancer, according...
FDA Grants Priority Review to Second-Line Pembrolizumab in Relapsed/Refractory Hodgkin Lymphoma
posted 20 hours
Shared 0 times
OncLive - The FDA has granted priority review to a new supplemental biologics license application for pembrolizumab monotherapy as a treatment for adult patients with relapsed/refractory...
know.lww.com - Adjuvant Osimertinib Delays...
Two Studies Report Secondary Surgery Extends Survival in Recurrent Ovarian Cancer – The ASCO Post
posted 21 hours
Shared 0 times
ASCO Post - Benefit Seen Solely in Selected Patients Treated at Specialized Centers By Alice Goodman Posted: 7/8/2020 2:12:00 PM Last Updated: 7/8/2020 2:45:12 PM Two phase...
Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC
posted 23 hours
Shared 2 times
OncLive - Benjamin Weinberg, MD, shares the clinical implications of how data from the 2020 ASCO Virtual Scientific Program may impact in the treatment of patients...
Adding a #mAb to PI + IMiD® + steroid triplet might be the winner approach at frontline but, do all antibodies add the same benefit? Will quadruplets become a #SOC for all patients with NDMM? Read our review on latest updates from #ASCO20 #EHA25 https://t.co/u1b3oxw7ld #mmsm https://t.co/u1b3oxw7ld